Healthcare Equities

The companies that provide, support or coordinate medical goods and services. This sector spans a broad range of activities – including the development and manufacture of medical equipment, pharmaceuticals and other treatments. Activities range from research to manufacturing, administration, insurance and facilities management. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals and specialty pharmaceuticals.

Roche (SIX: ROC) acquires 89bio for $3.5bn >

Finlay Mathers | Healthcare | Comment | 2 hours ago

Oryzon Genomics (BME: ORY) strengthens intellectual property profiles >

Arron Aatkar, PhD | Healthcare | Comment | 2 days ago

SEE ALL COMMENTARY >

KALA BIO (KALA)

Latest price

USD17.47

▾ −0.85 (−4.64)

As at 17/09/2025

Market capitalisation: USD129m

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: PISCES decoded – what is it and why was it created?

Edison explains: Climate accountability – hidden emissions or financial reality?

MediaWatch – A two-tier story

Audiovisual

Latest

Earnz – executive interview

Global Fashion Group – executive interview

OSE Immunotherapeutics – executive interview

About Edison

About Edison

Careers

Healthcare Equities

KALA BIO (KALA)

USD17.47

Medigene (MDG1)

EUR0.13

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Medigene – executive interview

See morecontent on

Mendus (IMMU)

SEK6.91

Mendus — Steady progress throughout Q225

Mendus – executive interview

Mendus — Clinical activities on track

See morecontent on

Newron Pharmaceuticals (NWRN)

CHF9.64

Newron Pharmaceuticals — H125 results reflect evenamide progress

Newron Pharmaceuticals — ENIGMA-TRS 1 commences enrolment

Newron Pharmaceuticals — Evenamide enters ENIGMA-TRS programme

See morecontent on

Nykode Therapeutics (NYKD)

NOK1.50

Nykode Therapeutics — Repositioned to streamline clinical progress

See morecontent on

Ocugen (OCGN)

USD1.32

Ocugen — Novel cell therapies for retinal diseases

See morecontent on

Okyo Pharma (OKYO)

USD2.13

Okyo Pharma — Targeting underserved corneal diseases

See morecontent on

Oncopeptides (ONCO)

SEK4.90

Oncopeptides — Targeted oncology with commercial momentum

See morecontent on

OpGen (OPGN)

—

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

See morecontent on

Oryzon Genomics (ORY)

EUR2.81

Oryzon Genomics — Foray into sickle cell disease

Oryzon Genomics — Making headway rolling into H225

Oryzon Genomics – executive interview

See morecontent on

OSE Immunotherapeutics (OSE)

EUR5.59

OSE Immunotherapeutics – executive interview

OSE Immunotherapeutics – executive interview

OSE Immunotherapeutics – equity proposition

See morecontent on

Percheron Therapeutics (PER)

AUD0.01

Percheron Therapeutics — Resetting the narrative with a VISTA focus

Percheron Therapeutics – executive interview

See morecontent on

Recce Pharmaceuticals (RCE)

AUD0.39

Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials

Recce Pharmaceuticals — Gearing up for an eventful year for R327G

Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on